摘要
目的:探讨放射治疗对中晚期宫颈癌耐药相关蛋白表达的影响及临床意义。方法:应用免疫组化法检测23例中晚期宫颈癌患者放疗前及放疗30Gy时宫颈癌组织中肺耐药蛋白(LRRP)、谷胱甘肽-S-转移酶(GST-л)、胸苷酸合成酶(TS)、拓扑异构酶Ⅱ(TopoⅡ)的表达。结果:放疗前LRRP的阳性表达率为47.8%,GST-л为56.5%,TS为30.4%,TopoⅡ为60.9%;放疗30Gy时LRRP的阳性表达率为69.6%,GST-л为73.9%,TS为73.9%,明显高于放疗前表达(P<0.05);TopoⅡ阳性表达率为13.0%,明显低于放疗前表达(P<0.05)。结论:放射治疗可以引起宫颈癌耐药相关蛋白表达改变,可能诱导或加强多药耐药(MDR)的形成。
OBJECTIVE: To investigate the effect and clinical significance of radiotherapy on the expression of muhidrug resistance- associated protein (MRP) in advanced cervical cancer. METHODS: The immunohistochemistry method was applied to detect the expression of lung resistance protein (LRRP), glutathione-S-transferases-π (GST-π), thymidylate synthetase (TS) and type Ⅱ topoisomerase (Topo Ⅱ ) in 23 patients with advanced cervical cancer before radiotherapy and after receiving 30 Gy dose radiation. RESULTS: The positive expression rates of LRRP, GST - π, TS and Topo Ⅱ before radiotherapy were 47.8%, 56.5%, 30.4% and 60.9%, respectively. The positive expression rates of LRRP, GST- π and TS in patients after 30 Gy dose radiation were 69.6%, 73.9% and 73.9%, respectively, which were signficantly higher as compared before radiotherapy(P〈0.05). The positive expression rate of Topo Ⅱ was 13.0% after radiation, which was significantly lower as compared before radiotherapy(P〈0.05) . CONCLUSION: Radiotherapy might change the expression of MDR in advanced cervical cancer tissues, induce or enhance MDR.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第29期2290-2292,共3页
China Pharmacy
关键词
子宫颈癌
放射治疗
耐药相关蛋白
化学治疗
Cervical cancer
Radiotherapy
Multidrug resistance- associated protein (MRP)
Chemotherapy